Literature DB >> 33864929

Long-term functional alterations following prenatal GLP-1R activation.

Devon L Graham1, Haley S Madkour1, Brenda L Noble1, Chris Schatschneider2, Gregg D Stanwood3.   

Abstract

Evidence supporting the use of glucagon-like peptide-1 (GLP-1) analogues to pharmacologically treat disorders beyond type 2 diabetes and obesity is increasing. However, little is known about how activation of the GLP-1 receptor (GLP-1R) during pregnancy affects maternal and offspring outcomes. We treated female C57Bl/6 J mice prior to conception and throughout gestation with a long-lasting GLP-1R agonist, Exendin-4. While GLP-1R activation has significant effects on food and drug reward, depression, locomotor activity, and cognition in adults, we found few changes in these domains in exendin-4-exposed offspring. Repeated injections of Exendin-4 had minimal effects on the dams and may have enhanced maternal care. Offspring exposed to the drug weighed significantly more than their control counterparts during the preweaning period and demonstrated alterations in anxiety-like outcomes, which indicate a developmental role for GLP-1R modulation in the stress response that may be sex-specific.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anxiety; Brain; Development; Developmental programming; GLP-1; Pregnancy

Mesh:

Substances:

Year:  2021        PMID: 33864929      PMCID: PMC8555578          DOI: 10.1016/j.ntt.2021.106984

Source DB:  PubMed          Journal:  Neurotoxicol Teratol        ISSN: 0892-0362            Impact factor:   4.071


  94 in total

1.  Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial.

Authors:  Malin Nylander; Signe Frøssing; Helle V Clausen; Caroline Kistorp; Jens Faber; Sven O Skouby
Journal:  Reprod Biomed Online       Date:  2017-04-24       Impact factor: 3.828

2.  Glucagon-like peptide-1 secretion in women with gestational diabetes mellitus during and after pregnancy.

Authors:  C Lencioni; V Resi; F Romero; R Lupi; L Volpe; A Bertolotto; A Ghio; S Del Prato; P Marchetti; G Di Cianni
Journal:  J Endocrinol Invest       Date:  2011-06-07       Impact factor: 4.256

3.  The glucagon-like peptide 1 receptor agonist liraglutide attenuates placental ischemia-induced hypertension.

Authors:  Subhi Talal Younes; Kenji J Maeda; Jennifer Sasser; Michael J Ryan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-11-15       Impact factor: 4.733

4.  Effects of centrally-injected glucagon-like peptide-1 on pilocarpine-induced seizures, anxiety and locomotor and exploratory activity in rat.

Authors:  Guldal Gulec; Naciye Isbil-Buyukcoskun; Nevzat Kahveci
Journal:  Neuropeptides       Date:  2010-03-12       Impact factor: 3.286

5.  PREPP: postpartum depression prevention through the mother-infant dyad.

Authors:  Elizabeth A Werner; Hanna C Gustafsson; Seonjoo Lee; Tianshu Feng; Nan Jiang; Preeya Desai; Catherine Monk
Journal:  Arch Womens Ment Health       Date:  2015-08-02       Impact factor: 3.633

6.  Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor.

Authors:  Krystyna Tatarkiewicz; Emmanuel J Sablan; Clara J Polizzi; Christiane Villescaz; David G Parkes
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-01-29       Impact factor: 3.619

Review 7.  Newer GLP-1 receptor agonists and obesity-diabetes.

Authors:  Emily Brown; Daniel J Cuthbertson; John P Wilding
Journal:  Peptides       Date:  2018-02       Impact factor: 3.750

8.  GLP-1 analog attenuates cocaine reward.

Authors:  D L Graham; K Erreger; A Galli; G D Stanwood
Journal:  Mol Psychiatry       Date:  2012-10-23       Impact factor: 15.992

9.  The glucagon-like peptide 1 analogue Exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice.

Authors:  Emil Egecioglu; Jörgen A Engel; Elisabet Jerlhag
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240

Review 10.  Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease.

Authors:  Elliot J Glotfelty; Lars Olson; Tobias E Karlsson; Yazhou Li; Nigel H Greig
Journal:  Expert Opin Investig Drugs       Date:  2020-05-15       Impact factor: 6.206

View more
  1 in total

1.  Behavioral and Neuroanatomical Consequences of Cell-Type Specific Loss of Dopamine D2 Receptors in the Mouse Cerebral Cortex.

Authors:  Gloria S Lee; Devon L Graham; Brenda L Noble; Taylor S Trammell; Deirdre M McCarthy; Lisa R Anderson; Marcelo Rubinstein; Pradeep G Bhide; Gregg D Stanwood
Journal:  Front Behav Neurosci       Date:  2022-01-13       Impact factor: 3.558

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.